Phase 1 Clinical Trial of EVOLVE104 Continues to Advance According to PlanOral Minisymposium Presentation Demonstrates That EVOLVE T Cell ...
A groundbreaking study published in Research (2025, DOI: 10.34133/research.0545) has elucidated the molecular mechanisms by which protein phosphatase 2A (PP2A) regulates CD8+ T cell-mediated immune ...
Immunotherapy has transformed cancer care, offering a way to harness the body’s own immune system to fight tumors. But even with these advances, many patients still don’t respond. One major barrier to ...
Results of the single-center, phase 2 CAR-PRISM (PRecision Intervention Smoldering Myeloma) clinical trial, the first to ...
A detailed analysis of T-cell redirecting therapies in oncology, comparing the mechanisms of bispecific antibodies and CAR T ...
Scientists have discovered how two transcription factors form a reciprocal regulatory circuit that controls T-cell exhaustion and migration during viral infection, which may inform future therapeutic ...
Commercialization ready compound supports a new method of generating highly functional human CAR-T cells for treating infectious diseases and cancer In experimental models, human CAR-T cells ...
CD8+ T cells divide cysteine between pathways that control growth and cancer-killing activity. Adjusting its use can enhance ...
A common eye-health nutrient, zeaxanthin, may also help the body fight cancer more effectively. Scientists discovered it strengthens T cells and enhances the impact of immunotherapy treatments. Found ...
The MarketWatch News Department was not involved in the creation of this content. Commercialization ready compound supports a new method of generating highly functional human CAR-T cells for treating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results